13.JPG)
The Global Clinical Trial Investigative Site Network Market Size is valued at 7.99 billion in 2023 and is predicted to reach 14.25 billion by the year 2031 at an 7.70% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The need for investigative site networks is driven by the fact that clinical trials are essential in establishing the effectiveness and legitimacy of new medicines.
- Clinical trials are in high demand due to the rising incidence of chronic diseases. These include cancer, heart problems, and neurological disorders.
- North America dominated the market and accounted for a revenue share of global revenue in 2023.
- Clinical trials are subject to a complicated and ever-changing regulatory scenario. Networks at investigational sites are subject to difficult and expensive regulatory standards.
The regulatory role is supported, participant enrollment is improved, data management is facilitated, and quality assurance is facilitated using a clinical trial investigative site network. It contributes to quicker trial initiations and shorter trial timeframes while increasing process compliance and reducing difficulties with each trial. These elements support the demand for networks of clinical investigative sites. The increased number of clinical trials is rising due to increased R&D spending and the desire for innovative therapies for uncommon diseases, which is, in turn, increasing the demand for clinical trial investigative site network services. The need for complex research and innovative treatments is being driven by the rising burden of diseases around the world, which is also anticipated to spur growth in these fields.
Since managing research sites and conducting clinical trials can be improved, pharmaceutical industry innovators are constantly coming up with new ideas. Outsourcing various trial operations to a specialist service provider, like site management organizations (SMOs), has emerged as a practical option for many developers among the alternatives. Employing such specialized service providers has many benefits, including helping sponsors meet their clinical research timeframes. A sizable growth rate is projected for the worldwide clinical investigative site network market. The accessibility of sites and the growing global reach of clinical trials are to blame for the growth.
Competitive Landscape
Some major key players in the Global Clinical Trial Investigative Site Network Market:
- ICON Plc,
- Meridian Clinical Research,
- IQVIA Inc.,
- Clinedge,
- WCG,
- ClinChoice,
- Access Clinical Research,
- FOMAT Medical Research, Inc.,
- SGS, KV Clinical,
- SMO-Pharmina,
- Xylem Clinical Research,
- Aurum Clinical Research.
Market Segmentation:
The clinical trial investigative site network market is segmented on the therapeutic area, phase and end-use. Based on the therapeutic area, the market is segmented into oncology, cardiology, CNS, pain management, endocrine and others. Based on phase, the clinical trial investigative site network market is segmented into Phase I, II, III and IV. Based on the end users, the clinical trial investigative site network market is segmented into sponsor and CRO.
Based on the therapeutic area, the oncology segment is a major contributor to the clinical trial investigative site network market.
The market's leading segment is oncology. The high frequency of various types of cancer and the surge in financing for oncology-related research are driving the segment's expansion. Clinical research on new anti-cancer medications and therapies is also expanding. As more individuals lead sedentary lifestyles, cancer cases will likely increase in the upcoming years. The rising prevalence of cancer cases will significantly increase the need for cutting-edge anti-cancer therapies, driving up the number of oncology-based clinical trials and fostering industrial expansion simultaneously.
The phase III segment witnessed growth at a rapid rate.
Phase III grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the expected time. Phase III clinical studies are more complex than those in earlier phases and involve a more significant number of patients. Therefore, there is a greater need for clinical trial investigative site networks in this stage of clinical trials. As a result of the sample size and research design, which call for precision dosing at an ideal level, this phase also has the highest failure rate.
The North American clinical trial investigative site network market holds a significant revenue share in the region.
The North American clinical trial investigative site network market is expected to register the highest market share. This high proportion can be attributed to pharmaceutical companies in the US and Canada investing more in clinical research. Further, it is anticipated that positive government support for clinical trials in the United States will boost consumption of the home machine of clinical trial investigation sites. Besides, the Asia Pacific region is estimated to hold the second-largest share of the market. Due to the ease of regulatory compliance, low study expenses, increasing patient population, and a few premier clinical institutions serving as sites, the area has become a hotspot for clinical trials.
Recent Development
- In May 2023, WCG has introduced the 360 Protocol Assessment, a comprehensive solution that meets the requirements of ICH E8 R1 and enhances the ability to forecast the outcome of clinical trials. This solution offers sponsors an evaluation of the operational risks and feasibility of the protocol, taking into account the perspectives of various stakeholders.
- In December 2022, Velocity Clinical Research acquired Meridian Clinical Research for an undisclosed sum. With around 80 sites in the U.S. and Europe, including a tech cluster in Hyderabad, India, the agreement establishes Velocity as the leading research site organization globally.
Global Clinical Trial Investigative Site Network Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 7.99 billion |
|
Revenue Forecast In 2031 |
USD 14.25 billion |
|
Growth Rate CAGR |
CAGR of 7.70% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Therapeutic Area, Phase, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
ICON Plc, Meridian Clinical Research, IQVIA Inc., Clinedge, WCG, ClinChoice, Access Clinical Research, FOMAT Medical Research, Inc., SGS, KV Clinical, SMO-Pharmina, Xylem Clinical Research, and Aurum Clinical Research. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
